Business Context and Reporting Period
This Form 8-K was filed by Conduit Pharmaceuticals Inc. (CDT) on August 6, 2024. The filing reports the entry into a material definitive agreement involving a new senior secured debt instrument and the issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
- Debt Instrument: Senior Secured Promissory Note with an original principal amount of $2,650,000.
- Issuance Discount: The note includes a $500,000 original issuance discount.
- Funding Schedule: $1,675,000 issued upon execution; the remaining $475,000 is contingent upon the registration and effectiveness of the resale registration statement for the Closing Common Stock.
- Interest Rate: 12% per annum, accruing daily. In the event of default, the rate increases to 18%.
- Maturity Date: August 5, 2025.
- Equity Issuance: 12,500,000 shares of common stock issued to the purchaser (Nirland Limited) as part of the transaction.
- Collateral: The note is secured by all assets of the Company and its subsidiary.
- Guarantees: Guaranteed by the Company's subsidiary and personally by Dr. Andrew Regan, a Board member.
Material Changes and Covenants
The filing discloses a significant increase in the Company's debt obligations and equity dilution. Key covenants include:
- Mandatory Prepayment: The Company must use portions of proceeds from future financings to mandatorily prepay the Note and accrued interest.
- Voluntary Prepayment: The Company may prepay the outstanding principal and accrued interest at any time without a fee.
- Right of First Refusal: The purchaser holds a right of first refusal to participate up to 100% in any future equity or debt offerings until the Note is retired.
Outlook, Risks, and Contingencies
The filing does not provide specific financial guidance or management commentary regarding future revenue or operational outlook. However, it highlights several risks and contingencies:
- Liquidity Contingency: A portion of the debt funding ($475,000) is contingent on the successful registration of the Closing Common Stock for resale.
- Default Risk: An event of default triggers an interest rate penalty increase from 12% to 18%.
- Asset Encumbrance: All company assets are now pledged as security for this debt.
- Personal Liability: A Board member has provided a personal guarantee, indicating the severity of the financing terms.
Investor Verification Checklist
- Verify the status of the resale registration statement for the 12,500,000 shares to confirm the release of the remaining $475,000 funding.
- Review the Company's current cash position to assess its ability to service the 12% monthly interest payments.
- Confirm the extent of the "all assets" security interest and how it impacts future financing capabilities.
- Monitor for any future financing rounds, as the Company is obligated to use proceeds to prepay this note and the lender has a right of first refusal.